K Pharma Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
4896
- Share Price
-
$4.15
- (As of Friday Closing)
K Pharma General Information
Description
K Pharma Inc is a company involved in Research, development, manufacturing, sales, and marketing of pharmaceutical products and regenerative medicine products. It is involved in the study of iPs cells in regenerative medicine to treat neurological conditions such as cerebral infarction and SCI.
Contact Information
Website
www.kpharma.co.jpCorporate Office
- 8th Floor Tri-Seven Roppongi
- 7-7-7 Roppongi, Minato-ku
- Tokyo, 106-0032
- Japan
Corporate Office
- 8th Floor Tri-Seven Roppongi
- 7-7-7 Roppongi, Minato-ku
- Tokyo, 106-0032
- Japan
K Pharma Stock Performance
As of 13-Nov-2026, K Pharma’s stock price is $4.15. Its current market cap is $48.3M with 11.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $4.15 | $4.33 | $3.88 - $6.03 | $48.3M | 11.6M | 21.7K | -$0.58 |
K Pharma Financials Summary
As of 30-Jun-2026, K Pharma has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 42,703 | 39,442 | 28,575 | 45,308 |
| Revenue | 0 | 0 | 0 | 7,117 |
| Net Income | (6,743) | (6,636) | (5,589) | 1,853 |
| Total Assets | 15,857 | 18,790 | 14,985 | 23,498 |
| Total Debt | 10,112 | 9,589 | 0 | 0 |
K Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
K Pharma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
K Pharma Patents
K Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025263405-A1 | Biomarker and method for determination, monitoring, stratification, and prediction and determination of disease-modifying drug therapeutic effect in amyotrophic lateral sclerosis | Pending | 18-Jun-2024 | ||
| WO-2025164698-A1 | Therapeutic agent and therapeutic composition for huntington's disease | Pending | 31-Jan-2024 | ||
| EP-4803079-A1 | Therapeutic agent for frontotemporal lobar degeneration and therapeutic composition | Pending | 02-Nov-2023 | ||
| WO-2025095099-A1 | Therapeutic agent for frontotemporal lobar degeneration and therapeutic composition | Inactive | 02-Nov-2023 | ||
| EP-4606888-A1 | Novel production method for neural stem cell/neural progenitor cell | Pending | 20-Oct-2022 | C12N5/0623 |
K Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
K Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
K Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
K Pharma FAQs
-
When was K Pharma founded?
K Pharma was founded in 2016.
-
Where is K Pharma headquartered?
K Pharma is headquartered in Tokyo, Japan.
-
What is the size of K Pharma?
K Pharma has 21 total employees.
-
What industry is K Pharma in?
K Pharma’s primary industry is Drug Discovery.
-
Is K Pharma a private or public company?
K Pharma is a Public company.
-
What is K Pharma’s stock symbol?
The ticker symbol for K Pharma is 4896.
-
What is the current stock price of K Pharma?
As of 13-Nov-2026 the stock price of K Pharma is $4.15.
-
What is the current market cap of K Pharma?
The current market capitalization of K Pharma is $48.3M.
-
What is K Pharma’s annual earnings per share (EPS)?
K Pharma’s EPS for 12 months was -$0.58.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
